RxDoctor Payments Data

Aloice Aluoch

Rheumatology · Snellville, GANPI 1245541259

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $25,387 of the $29,179 with a category attached, or 87.0%. 42 manufacturers reported payments, led by AbbVie at 25.7% of the total.

$29,179in general payments, 2019–2025

Across 1,184 payments — averaging $24.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$8K
  • Amgen$6K
  • Johnson & Johnson$5K
  • Pfizer$1K
  • Novartis$1K
  • UCB, Inc.$1K
  • plus $7K from 36 others

What the payments were for

  • Consulting fees$2,1457%
  • Speaking & faculty fees$1,2004%
  • Travel & lodging$690%
  • Food & beverage$25,38787%
  • Education$3781%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$29,179 in reported general payments places this provider in the 85th percentile of 177 rheumatology providers in Georgia.

See all rheumatology providers in Georgia

Medicare billing

Part B allowed, 2024
$823,629
Medicare patients
199
Services billed
47,012

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RinvoqUpadacitinib99$713,761
Enbrel SureclickEtanercept72$529,224
Orencia ClickjectAbatacept25$134,495
BenlystaBelimumab26$117,894
OtezlaApremilast16$100,995
OrenciaAbatacept/Maltose11$72,588
KevzaraSarilumab16$67,395
Xeljanz XrTofacitinib Citrate12$63,464
ProliaDenosumab11$19,114
Hydroxychloroquine Sulfate415$14,067
SavellaMilnacipran Hcl11$8,448
MethotrexateMethotrexate Sodium150$3,596
Duloxetine Hcl102$1,782
Leflunomide32$1,693
Diclofenac Sodium42$1,438

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq, Savella$7,510$722,210110 claims
AmgenOtezla, Prolia$6,348$120,10927 claims
GSKBenlysta$1,041$117,89426 claims
E.r. Squibb & Sons, L.L.C.Orencia$200$72,58811 claims
SanofiKevzara$140$67,39516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 177 rheumatology providers in Georgia.

Other rheumatology in Snellville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →